<table>
<thead>
<tr>
<th>Title</th>
<th>Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Author(s)</td>
<td>Harrell, Daniel Toshio</td>
</tr>
<tr>
<td>Citation</td>
<td>Nagasaki University (長崎大学), 博士 (医学) (2018-03-31)</td>
</tr>
<tr>
<td>Issue Date</td>
<td>2018-03-31</td>
</tr>
<tr>
<td>URL</td>
<td><a href="http://hdl.handle.net/10069/38214">http://hdl.handle.net/10069/38214</a></td>
</tr>
<tr>
<td>Rights</td>
<td>© 2015 Elsevier Ireland Ltd. All rights reserved.</td>
</tr>
</tbody>
</table>

NAOSITE: Nagasaki university’s Academic Output SITE
http://naosite.lb.nagasaki-u.ac.jp
Genotype-dependent differences in age of manifestation and arrhythmia complications in short QT syndrome

Daniel Toshio Harrella, Takashi Ashihara b, Taisuke Ishikawa a, Ichiko Tominaga a,1, Andrea Mazzantic, Kazuhiro Takahashid, Yasushi Ogino sawae, Haruhiko Abe f, Koji Maemurag, Naokata Sumitomo h, Kikuya Uno i, Makoto Takano j, Silvia G. Prioric, k, Naomasa Makita a,☆

a Department of Molecular Physiology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
b Department of Cardiovascular and Respiratory Medicine, Shiga University of Medical Science, Heart Rhythm Center, Shiga, Japan
c Molecular Cardiology, IRCCS Salvatore Maugeri Foundation, Pavia, Italy
d Department of Pediatric Cardiology, Okinawa Children’s Medical Center, Okinawa, Japan
e Second Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
f Department of Heart Rhythm Management, University of Occupational and Environmental Health, Kitakyushu, Japan
g Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
h Department of Pediatric Cardiology, Saitama International Medical Center, Hidaka, Japan
i Sapporo Heart Center, Sapporo, Japan
j Department of Physiology, Kurume University School of Medicine, Kurume, Japan
k Department of Molecular Medicine, University of Pavia, Pavia, Italy

Article info

Article history:
Received 7 February 2015
Received in revised form 3 April 2015
Accepted 14 April 2015
Available online 15 April 2015

Keywords:
Short QT syndrome
Mutation
Patch clamp
Meta-analysis
Computer simulation

Abstract

Background: Short QT syndrome (SQTS) is a rare inheritable arrhythmia, associated with atrial and ventricular fibrillations, caused by mutations in six cardiac ion channel genes with high penetrance. However, genotype-specific clinical differences between SQTS patients remain to be elucidated.

Methods and results: We screened five unrelated Japanese SQTS families, and identified three mutations in KCNH2 and KCNQ1. A novel mutation KCNH2-I560T, when expressed in COS-7 cells, showed a 2.5-fold increase in peak current density, and a positive shift (+14 mV) of the inactivation curve compared with wild type. Computer simulations recapitulated the action potential shortening and created an arrhythmogenic substrate for ventricular fibrillation. In another family carrying the mutation KCNQ1-V141M, affected members showed earlier onset of manifestation and frequent complications of bradyarrhythmia. To determine genotype-specific phenotypes in SQT1 (KCNH2), SQT2 (KCNQ1), and other subtypes SQT3–6, we analyzed clinical variables in 65 mutation-positive patients among all the 132 SQTS cases previously reported. The age of manifestation was significantly later in SQT1 (SQ1: 35 ± 19 years, n = 30; SQ2: 17 ± 25 years, n = 8, SQ3–6: 19 ± 15 years, n = 15; p = 0.011). SQT2 exhibited a higher prevalence of bradyarrhythmia (SQ2: 6/8, 75%; non-SQT2: 5/57, 9%; p < 0.001) and atrial fibrillation (SQ2: 5/8, 63%; non-SQT2: 12/57, 21%; p = 0.012). Of 51 mutation-positive individuals from 16 SQTS families, nine did not manifest short QT, but exhibited other ECG abnormalities such as atrial fibrillation. The resulting penetrance, 82%, was lower than previously recognized.

Conclusion: We propose that SQTS patients may exhibit different clinical manifestations depending upon their genotype.

© 2015 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

Short QT syndrome (SQTS)3 is a rare, inheritable cardiac electrical disease characterized by a shortened corrected QT interval (QTc)3 and associated with a risk of sudden cardiac death (SCD),4 ventricular fibrillation (VF), and atrial fibrillation (AF), but without structural abnormalities [1,2]. SQTS is characterized by accelerated cellular repolarization, owing to either an enhanced outward repolarizing potassium current or a reduced inward depolarizing calcium current. To date, mutations responsible for SQTS have been identified in six ion channel...
2. Methods

2.1. Study cohorts

We studied five unrelated Japanese families consisting of 10 affected family members. The QT interval was corrected for heart rate using Bazett’s equation \( QTc = QT / \sqrt{RR} \). The diagnosis of SQTS was made based on QTc ≤ 330 ms or QTc ≤ 360 ms with presence of VF episode, pathogenic mutations, or family history of SQTS or SCD before age of 40 years [20]. All individuals who participated in the study gave written informed consent prior to genetic and clinical investigations in accordance with the standards of the Declaration of Helsinki and the local ethics committees at each participating institution. To further characterize the genotype-specific characteristics, we created an additional cohort, which consisted of 132 SQTS patients including five mutations, or family history of SQTS or SCD before age of 40 years [20]. All individuals who participated in the study gave written informed consent prior to genetic and clinical investigations in accordance with the standards of the Declaration of Helsinki and the local ethics committees at each participating institution.

2.2. Genetic analysis

Genomic DNA was extracted from the blood by a standard protocol. All the exons of \( KCNH2 \), \( KCNQ1 \), and \( KCNJ2 \) were PCR amplified as previously described [21–23] (Supplemental Table S2). Direct sequencing was performed using the ABI Genetic Analyzer 3130 (Life Technologies, Carlsbad, CA).

2.3. Biophysical analysis of \( KCNH2-I560T \)

Site-directed mutagenesis was performed using the QuickChange site-directed mutagenesis kit (Agilent Technologies, Santa Clara CA) on human \( KCNH2 \) cDNA cloned in an expression plasmid pcDNA3.1 (Life Technologies). Oligonucleotide sequences are available in Supplemental Table S2. The COS-7 cell line was transiently transfected with wild-type (WT) or I560T-\( KCNH2 \) plasmid, and the potassium current was recorded by whole-cell patch-clamp techniques as previously described [24] with modifications.

2.4. Western blotting

To test the cell surface expression and the glycosylation of the I560T mutant channel protein, we carried out Western blotting analysis using WT channel and a neighboring LQTS mutation A561V as a control which is characterized by the membrane trafficking defect [25]. HEK cells were transfected with \( KCNH2 \) plasmid of either WT, I560T, or A561V and the proteins extracted from the cell lysate were subjected to Western blotting as described previously [26]. Anti-\( KCNH2 \) polyclonal antibodies (1:400, Life Technologies) and anti-I\( \alpha \) actin polyclonal antibodies (1:200, Cell Signaling Technology, Danvers, MA) were used as primary antibodies, and the signals were visualized by ECL Prime Detection Reagent (GE Healthcare).

2.5. Computer simulation of action potential shortening and inducibility of lethal ventricular arrhythmia in \( KCNH2-I560T \)

Computer simulations were carried out to determine whether the gating abnormalities and the increased current density of the \( KCNH2-I560T \) are sufficient to cause shortening of the action potential duration (APD) and QT interval. Membrane kinetics were represented by the O’Hara-Rudy dynamic human ventricular model with modified Markovian \( I_{Ks} \) equations [27–29], and the pseudo-ECG was calculated as described previously [30]. To demonstrate the relative arrhythmogenicity of \( KCNH2-I560T \), we conducted simulations of VF in the bidomain endocardial sheet, and an S1–S2 cross-field protocol was applied to induce a spiral wave reentry.

2.6. Clinical characteristics of SQTS with different genotypes

In the study cohort of 132 SQTS patients, 65 patients were mutation-positive (6 from the current study and 59 from previous reports [6–9, 12–19]) of whom 30 (46%) were male and had a mean age of manifestation of 28 ± 20 years (ranging from 0 to 72). Clinical variables for each reported patient were extracted for sex, age of manifestation, QT, QTc, heart rate (HR), causative gene and mutation, and clinical history: AF, SCD/cardiac arrest, palpitations/syncope, and sick sinus syndrome/bradycardia. Bradycardia for adult patients was evaluated based on HR < 50 bpm. For children, bradycardia was determined based on HR < 100 bpm for ages 0 to 3 years and on HR < 60 bpm for ages 3–9 years [31]. A patient was considered symptomatic in the presence of the aforementioned clinical episodes.

2.7. Statistical analysis

Data are reported as mean ± SD and analyzed by one-way ANOVA with Bonferroni correction. The univariate clinical variables are presented as percentages, and analyzed by \( \chi^2 \)-test or Fisher exact test. Statistical significance was set at \( p < 0.05 \).

---

5 LQTS: long QT syndrome.

6 APD: action potential duration.
3. Results

3.1. Case presentation and genetic analysis of SQTS families (Figs. 1 and 2, and Table 1)

3.1.1. Family 1

A 64-year-old man experienced palpitations and near syncope due to paroxysmal AF and atrial flutter, for which he underwent catheter ablation (Fig. 1A). After the catheter ablation, short QT (QTc = 319 ms, HR = 68 bpm) with peaked T waves on the precordial leads became manifested, and he was diagnosed with SQTS (Supplemental Fig. S1). His father and brother died suddenly from unknown causes. Genetic screening revealed a novel heterozygous missense mutation in exon 7 of KCNH2 (c.1679T>T), resulting in the amino acid substitution I560T, located in transmembrane segment S5 (Fig. 2A). KCNH2-I560T was absent in the genomic DNA of 200 healthy Japanese individuals, and in the public databases: dbSNP; 1000 Genomes project; Exome Variant Server; and Human Genetic Variation Database. The amino acid residue I560 is 100% conserved among eight different species (Fig. 2B). The proband has no offspring, and declined insertion of an implantable cardioverter defibrillator (ICD).

3.1.2. Family 2

A 39-year-old woman with aborted VF was diagnosed with SQTS (QTc = 322 ms, HR = 74 bpm) and had an ICD implanted (Fig. 1B, Supplemental Fig. S1, B). Combined prescription of bepridil with bisoprolol successfully prolonged her QTc to 341 ms, and she has been free from VF attack for 2 years. Her father died suddenly from unknown causes. Genetic screening identified a novel heterozygous missense mutation T618I (c.1853C>T) located in the pore region. This mutation was previously reported [14].

3.1.3. Family 3

The index patient, a 10-year-old girl, was diagnosed with congenital sick sinus syndrome (SSS) due to fetal bradycardia (HR = 72 bpm) at the gestational age of 22 weeks (Fig. 1C). She was born by cesarean section at the age of 37 weeks, and exhibited sinus bradycardia (HR = 50 bpm) with bradycardia-induced heart failure, although echocardiography showed no organic heart diseases. As a result of a complete atrioventricular block at the age of 12 days, a permanent pacemaker was implanted. At 4 years of age, the patient demonstrated severe QT shortening (QTc = 280 ms) with bradycardia (HR = 64 bpm) (Supplemental Fig. S1, C). Genetic screening revealed a heterozygous missense mutation V141M (c.421G>A) of KCNQ1 located in transmembrane segment S1 (Fig. 2D). This mutation was previously reported [15]. Her father had experienced chronic AF with bradycardia since the age of 3 years, but recorded a QTc value of 375 ms (HR = 37 bpm) by ECG, which is outside the diagnostic criteria of SQTS (Supplemental Fig. S1, D) [20]. Interestingly, despite this, he carried the V141M mutation. Her paternal grandfather had a pacemaker implanted at the age of 50 years, but declined genetic testing.

3.1.4. Family 4

A 17-year-old woman who survived an episode of VF was diagnosed with SQTS (QTc = 330 ms, HR = 83 bpm), and an ICD was implanted (Fig. 1D, Supplemental Fig. S1, E). Her sister and grandmother also displayed short QT. Genetic screening was negative.

3.1.5. Family 5

A 42-year-old man exhibited short QT (QTc = 340 ms, HR = 53 bpm) without presence of organic heart disease (Fig. 1E). Coved-type ST elevation on V1 and V2 was observed after intravenous...
administration of pilsicainide, indicating a complication of Brugada syndrome (Supplemental Fig. S1, F). A programmed electrical stimulation failed to induce VF. His mother died at 43 years and an uncle died suddenly from unknown causes. Genetic testing was negative for all six SQTS genes, as well as Brugada syndrome candidate genes including SCN5A, HCN4, KCND3, KCNE3, SCN1B, SCN3B, SCN10A, and TRPM4. An ICD was implanted as a primary preventative measure.

3.2. Electrophysiological properties of KCNH2-I560T

KCNH2-I560T heterologously expressed in COS-7 cells resulted in a significant 2.5-fold increase in the peak $I_{Kr}$ current density versus WT (I560T: 99.7 ± 10.2 pA/pF; WT: 40.6 ± 10.4 pA/pF; p < 0.005) (Fig. 3A,B), whereas the voltage dependence of activation was comparable (I560T: −19.7 ± 3.2 mV; WT: −18.5 ± 1.6 mV; NS) (Fig. 3C).

Table 1
Summary of clinical characteristics of SQTS families.

<table>
<thead>
<tr>
<th>Family</th>
<th>Proband/family</th>
<th>Gender</th>
<th>Age of manifestation (year)</th>
<th>QTc (ms)</th>
<th>Mutations</th>
<th>Arrhythmias</th>
<th>Symptoms</th>
<th>Family history</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Proband</td>
<td>M</td>
<td>64</td>
<td>319</td>
<td>KCNH2-I560T</td>
<td>Paroxysmal AF, AFL</td>
<td>Palpitation, syncope</td>
<td>SCD</td>
</tr>
<tr>
<td>2</td>
<td>Proband</td>
<td>F</td>
<td>39</td>
<td>322</td>
<td>KCNH2-T618I</td>
<td>Aborted VF</td>
<td>Palpitation</td>
<td>SCD</td>
</tr>
<tr>
<td></td>
<td>Brother</td>
<td>M</td>
<td>42</td>
<td>330</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Nephew</td>
<td>M</td>
<td>14</td>
<td>330</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>Proband</td>
<td>F</td>
<td>4*</td>
<td>280</td>
<td>KCNQ1-V141M</td>
<td>SSS, fetal bradycardia</td>
<td>–</td>
<td>PPM</td>
</tr>
<tr>
<td></td>
<td>Father</td>
<td>M</td>
<td>37</td>
<td>375</td>
<td></td>
<td></td>
<td>Chronic AF, bradycardia</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>Proband</td>
<td>F</td>
<td>17</td>
<td>330</td>
<td>Negative</td>
<td>Aborted VF</td>
<td></td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Sister</td>
<td>F</td>
<td>19</td>
<td>327</td>
<td></td>
<td></td>
<td></td>
<td>–</td>
</tr>
<tr>
<td></td>
<td>Grandmother</td>
<td>F</td>
<td>77</td>
<td>321</td>
<td></td>
<td></td>
<td></td>
<td>–</td>
</tr>
<tr>
<td>5</td>
<td>Proband</td>
<td>M</td>
<td>42</td>
<td>340</td>
<td>Negative</td>
<td>BrS</td>
<td></td>
<td>–</td>
</tr>
</tbody>
</table>


*: Diagnosed at 10 years. Severe short QT (QTc = 280 ms) demonstrated at 4 years.
Steady-state inactivation showed a 14 mV positive shift in the mutant channel (I560T: $-13.2 \pm 4.1$ mV; WT: $-27.3 \pm 2.4$ mV; $p < 0.005$). The slope factor was nearly identical (I560T: $-26.5 \pm 1.2$ mV; WT: $-25.4 \pm 1.1$ mV; NS) (Fig. 3E). These results suggest that the mutant channel may cause a gain of function in $I_{Ks}$ current, which is a known trait of SQTS caused by KCNH2 mutations.

3.3. Protein expression of KCNH2-I560T

To test if the $I_{Ks}$ gain of function observed in the KCNH2-I560T channel may be attributed to increased membrane expression levels or hyperglycosylation of the mutant channel protein, we performed Western blotting using a trafficking-defective neighboring KCNH2 mutation.
A561V as a control [25]. While the A561V mutant showed only minimal expression of mature glycosylated high-molecular-weight protein, the I560T mutant showed nearly identical expression levels and pattern to the WT protein (Fig. 3F). This confirms that the gain of function in \( I_{Kr} \) observed in the I560T mutant is not due to the altered membrane expression but most likely due to the changes in channel gating properties.

### 3.4. In silico simulation of KCNH2-I560T

To explore whether the relatively modest gating modulation caused by the \( KCNH2-1560T \) mutation is sufficient to cause shortening of APD and QT interval, we performed simulations of human ventricular action potentials with and without the \( KCNH2-1560T \) mutation in the 1-D myofiber model, representing the electrical behaviors of the left ventricle. These simulations involved detailed modeling of ion channel dynamics, including \( I_{Ks} \) and other relevant current components, to assess the impact on action potential duration (APD) and QT interval.

**Fig. 4.** Simulations of Markovian \( I_{Ks} \) action potentials, ECGs, and effect on ventricular arrhythmogenicity of KCNH2-I560T. (A–C) Current–voltage relationship, voltage dependence of activation, and steady-state inactivation curves generated from the Markovian \( I_{Ks} \) model. (D) Using the myofiber model incorporating the above Markovian \( I_{Ks} \) models, transmural dispersions of action potentials with WT and I560T mutation were made. The spatial distributions of membrane potentials were color coded according to the color bar. Endo, M, and Epi denote endocardial, mid-myocardial, and epicardial layers. (E and F) Simulated ECGs and consecutive snapshots of the myocardial sheet model, incorporating the Markovian \( I_{Ks} \) models, after S1–S2 cross-field stimulation are shown. White open arrows and double short lines indicate the direction of wave front propagation and collision between wave fronts, respectively. Curved thin white lines inside the snapshots represent trajectories of the spiral wave phase singularities during the last 500 ms of activity.
ventricular free wall. Using a modified computer model of Markovian IKo, we were able to faithfully reproduce the IKo current traces and tail currents (Supplemental Fig. S2), 2.5-fold increase in current density (Fig. 4A), no significant shift in activation (Fig. 4B), and a 14 mV positive shift in inactivation (Fig. 4C), consistent with our observations in vitro. When cells were stimulated at 1 Hz, KCNH2-I560T showed significantly shorter APD than WT (Fig. 4D). The resulting pseudo-ECG also showed an abbreviated QT interval for the KCNH2-I560T mutant (287 ms) compared with WT (388 ms), which meets the diagnostic criteria of SQTS.

To explore the arrhythmogenic potency of VF in KCNH2-I560T, an S1–S2 cross-field protocol, with onset of S2 assumed as time zero (0 ms panel), was applied to induce a spiral wave re-entry (as a model of VF) (Fig. 4E,F). In the WT model, a counter-clockwise rotating wavefront terminated immediately (75–150 ms panels) and sustained re-entry was not induced. In contrast, the KCNH2-I560T model elicited a sustained meandering spiral wave re-entry with mean cycle length of ~153 ms (Supplemental videos S1 and S2).

3. Genotype-dependent differences in clinical characteristics of SQTS

Based on the observations in our SQTS cohort, that KCNQ1 mutation carriers showed apparently earlier onset and more frequent bradyarrhythmia complications (Fig. 1, Table 1), we explored potential genotype-specific characteristics in the broader SQTS patient population. We combined mutation-positive SQTS patients of our cohort (n = 6) and those from previous publications (n = 59), and analyzed the clinical variables with respect to different genotypes (Tables 2 and 3). Among the SQT1, SQT2, and SQT3–6 groups, the age of manifestation was significantly later in SQT1 patients (SQT1: 35 ± 19 years, n = 30; SQT2: 17 ± 25, n = 8; SQT3–6: 19 ± 15, n = 15; p = 0.011), whereas the QTc values were comparable (Fig. 5, Table 2). Conversely, complications of SSS or bradycardia were significantly more prevalent in SQT2 patients (6/8, 75%) than non-SQT2 patients (5/57, 9%; p = 0.001) (Fig. 5C, Table 3), whereas there was no difference between SQT1 and non-SQT1 (Table 3). Furthermore, the prevalence of AF was also present in SQT2 patients (5/8, 63%) than non-SQT2 patients (12/57, 21%, p = 0.012) (Fig. 5D, Table 3). Other clinical parameters did not show significant differences between genotypes (Tables 2 and 3).

3.6. Evaluation of penetrance in 16 SQTS families

SQTS has been described as having close to complete penetrance in cohort studies, with only some exceptional cases with normal QTc [8, 9]. Despite carrying the mutation KCNQ1-V141M, the father of family 3 exhibited a QTc of 375 ms, which is outside the diagnostic criteria for SQTS [20], but manifested chronic AF and bradycardia, prompting us to reevaluate the genetic penetrance of SQTS (Fig. 1C, Supplemental Fig. S1, D). Among 35 SQTS families, we focused on two families from our study and 14 previously reported families [1,3,5–9,12,14,32–36] with two or more genetically or phenotypically affected individuals (Table 4). Our family 3 was the only SQTS family in this group carrying a KCNQ1 mutation. Among a total of 51 mutation-positive individuals, only 42 exhibited short QTc < 360 ms. Therefore, the calculated overall genetic penetrance of SQTS was 82%, which was lower than previously recognized [8,9]. Furthermore, we found that the 13 families with K channel mutations (SQT1–3) showed a higher penetrance of 90%, whereas Ca channel mutations (SQT4–6) showed a much lower penetrance of 58%. Interestingly, the low penetrance observed in families with Ca channel mutations is comparable to the well-known incomplete penetrance associated with Brugada syndrome [37]. Of the nine mutation carriers who did not exhibit short QTc, four K channel mutation carriers exhibited syncope, AF, bradycardia, or instances of non-documented arrhythmia [35,36], and the five patients with Ca channel mutations remained asymptomatic [6,7].

4. Discussion

4.1. Common electrophysiological properties in KCNQ2 mutations

The novel KCNQ2 mutation I560T was identified in an SQT1 patient with severe QTc shortening, and family history of sudden death. Investigation of the KCNQ2-I560T channel expressed in COS-7 cells showed a relatively mild gain of function with a +14 mV shift of steady-state inactivation but no activation abnormalities. The computer simulation recapitulated the APD shortening and susceptibility to ventricular reentry. Among four KCNQ2 mutations that have been functionally evaluated, N588K was associated with a severe QTc shortening and exhibited severe gain of function with a 4-fold increase in peak current density, virtually no inactivation over the physiological range, and a large positive shift (+102 mV) of steady-state inactivation [3,38]. Peak current density was increased 6-fold in both T618I and E50D, and the steady-state inactivation was shifted by +20 mV and +11.5 mV in T618I and E50D, respectively [8,14,39,40]. Taken together, these results suggest that augmented peak current density and a positive shift of steady-state inactivation are the functional channel properties commonly affected by KCNQ2 mutations responsible for SQT1. The precise mechanism for the positive shift in inactivation curve in KCNQ2-I560T is not clear, however, it is speculated that the shift in inactivation may be due to a disruption of the hydrogen bonding between amino acid residues that span the S5 and pore helix as seen in a neighboring residue HSV2 [41]. These changes in inactivation may be the primary determinants for the clinical manifestations of SQT1 [40]. However, as is observed in the SQT1 case carrying KCNQ2-I560T reported here, the degree of the gating abnormality and the clinical severity may not always correlate, suggesting the involvement of additional confounding factors. These may include a number of common genetic variations that modulate QTc, as suggested by genome-wide association studies of LQTS [42,43]. Similar mechanisms may underlie the difference between clinical severity of SQTS patients and the electrophysiological properties of the mutant channels.

4.2. Incomplete penetrance of SQTS

Penetrance in LQTS has been recognized to be as low as 25% for some mutations [44], with the latent LQTS mutant carriers still, however, at risk of lethal arrhythmias and SCD [11]. By contrast, nearly complete penetrance has been described in SQTS within cohort studies [8,9]. However, our meta-analysis of 16 SQTS families revealed an incomplete penetrance of 82%, where nine mutation-positive patients from six unrelated SQTS families exhibited longer QTc than 360 ms (Table 4). Responsible mutations for the latent SQTS cases include three K channel mutations: KCNQ1-V141M (family 3); KCNQ2-E50D [8,36]; and KCNQ2-R1135H [35]. The carriers of KCNQ1-V141M and KCNQ2-R1135H showed arrhythmias in the absence of short QTc. Three other mutations

Table 2

Age of manifestation and QTc of SQTS patients.

<table>
<thead>
<tr>
<th>Clinical characteristics</th>
<th>SQT1</th>
<th>SQT2</th>
<th>SQT3–6</th>
<th>p</th>
<th>Non-genotyped</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of manifestation (year)</td>
<td>35 ± 19 (30)</td>
<td>17 ± 25 (8)</td>
<td>19 ± 15 (15)</td>
<td>0.011</td>
<td>28 ± 18 (57)</td>
</tr>
<tr>
<td>QTc (ms)</td>
<td>307 ± 30 (31)</td>
<td>305 ± 33 (8)</td>
<td>329 ± 55 (21)</td>
<td>0.107</td>
<td>311 ± 27 (65)</td>
</tr>
</tbody>
</table>

Mean ± SD (n). * Comparison between SQT1, SQT2, and SQT3–6.
were found in Ca channel genes: CACNA1C-G490R, CACNB2-S481L and CACNA2D1-S755T. The carriers were asymptomatic [6,7]. The mechanisms underlying latent SQTS have not been determined; however, coexisting common polymorphisms that prolong repolarization may be potential candidates that mask the abbreviated QT intervals. In fact, among the mutant carriers of CACNA1C-G490R, an individual with a well-known KCNH2 polymorphism K897T [42] showed normal QTc, whereas the other two family members who only carry G490R manifested SQTS [6].

In SQT2, only three mutations (KCNQ1-V307L, -V141M, and -R259H) have to date been reported in de novo or sporadic cases [4,9,13,15,16] and our family 3 carrying V141M is the first familial instance of SQT2.

In view of the fact that the proband’s father has exhibited chronic AF since 3 years of age without manifesting SQTS, despite carrying the V141M mutation, there may be additional latent carriers who do not show ECG abnormalities or other arrhythmias such as AF in the absence of QT shortening. Lack of familial SQTS may be because the phenotypic manifestations of KCNQ1 mutations are milder than other subtypes, or because SQT2 has an extremely low penetrance. Further genetic screening of family members with non-remarkable ECG may help identify more latent KCNQ1 carriers and better understand the natural history of SQTS.

### 4.3. Genotype-specific clinical characteristics in SQTS

The age of manifestation of mutation-positive SQTS patients spans from in utero to the eighth decade of life [8]. However, the age-distribution of lethal events in SQTS shows two peaks; one at the first year of life and another between 20 and 40 years of age [9]. Because we found that the age of initial clinical manifestation in SQT1 was significantly later than other subtypes, and six KCNQ1 mutation carriers exhibited apparent early onset of bradyarrhythmia, it is speculated that two distinct peaks of the first arrhythmic events may also be attributed to two genotypes (Fig. 5A, Table 2). A similar genotype-dependent age of manifestation is well known in LQTS; the majority of LQT2 (KCNH2) patients manifest their first symptoms after puberty, whereas LQT1

### Table 3

<table>
<thead>
<tr>
<th>Genotype–phenotype comparison SQTS patients.</th>
<th>Clinical characteristics</th>
<th>SQT1 (n = 34)</th>
<th>non-SQT1* (n = 31) p†</th>
<th>SQT2 (n = 8)</th>
<th>non-SQT2§ (n = 57) p‡</th>
<th>Non-genotyped (n = 67)</th>
<th>p¶</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>18 (53%)</td>
<td>12 (39%)</td>
<td>0.25</td>
<td>2 (25%)</td>
<td>28 (49%)</td>
<td>0.19</td>
<td>50</td>
</tr>
<tr>
<td>Syncope/palpitation</td>
<td>8 (24%)</td>
<td>3 (10%)</td>
<td>0.123</td>
<td>0 (0%)</td>
<td>11 (20%)</td>
<td>0.17</td>
<td>8</td>
</tr>
<tr>
<td>SCD/aborted cardiac arrest</td>
<td>6 (18%)</td>
<td>6 (19%)</td>
<td>0.86</td>
<td>2 (25%)</td>
<td>10 (18%)</td>
<td>0.6</td>
<td>20</td>
</tr>
<tr>
<td>AF</td>
<td>8 (24%)</td>
<td>9 (29%)</td>
<td>0.614</td>
<td>5 (63%)</td>
<td>12 (21%)</td>
<td>0.012</td>
<td>11</td>
</tr>
<tr>
<td>SSS/bradycardia</td>
<td>4 (12%)</td>
<td>7 (23%)</td>
<td>0.245</td>
<td>6 (75%)</td>
<td>5 (9%)</td>
<td>&lt;0.001</td>
<td>7</td>
</tr>
</tbody>
</table>

*Non-SQT1 denotes SQT2–6.
§Non-SQT2 denotes SQT1 and SQT3–6.
†Comparison between SQT1 vs SQT2–6.
‡Comparison between SQT2 vs SQT1, 3–6.

Fig. 5. Genotype-dependent clinical characteristics observed in SQTS patients. (A) Dot represents the age of manifestation of each case. SQT1 patients exhibited significantly later onset than other SQTS subgroups (p = 0.011). Pairwise comparison also showed significant later manifestation in SQT1 than SQT2 (*: p = 0.043) as well as SQT1–6 (‡: p = 0.019). Non-genotyped SQTS, shown as a reference, exhibited a wide distribution. Boundaries of the box represent the 25th and 75th percentiles, and a line within a box marks the median. Whiskers of the box indicate the 10th and 90th percentiles. (B) QTc values were similar among SQTS subgroups. (C) Complications of SSS and bradycardia were significantly more prevalent in SQT2 than non-SQT2 subgroup (p < 0.001). (D) Complication of AF was significantly more prevalent in SQT2 patients than in non-SQT2 subgroup (p = 0.012).
Table 4
Mutations and the penetrance of 16 reported SQTS families.

<table>
<thead>
<tr>
<th>Family</th>
<th>Genes</th>
<th>Mutations</th>
<th>Affected (n)</th>
<th>Mutation-positive (n)</th>
<th>Penetrance (%)</th>
<th>Other complications</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>KCNH2</td>
<td>N588K</td>
<td>3</td>
<td>3</td>
<td>100</td>
<td>–</td>
<td>[1, 32]</td>
</tr>
<tr>
<td>2</td>
<td>KCNH2</td>
<td>N588K</td>
<td>3</td>
<td>3</td>
<td>100</td>
<td>–</td>
<td>[3, 33, 34]</td>
</tr>
<tr>
<td>3</td>
<td>KCNH2</td>
<td>N588K</td>
<td>4</td>
<td>4</td>
<td>100</td>
<td>–</td>
<td>[3, 33, 34]</td>
</tr>
<tr>
<td>4</td>
<td>KCNH2</td>
<td>N588K</td>
<td>3</td>
<td>3</td>
<td>100</td>
<td>–</td>
<td>[9]</td>
</tr>
<tr>
<td>5</td>
<td>KCNH2</td>
<td>R1135H</td>
<td>1</td>
<td>3</td>
<td>33</td>
<td>Syncope</td>
<td>[8, 36]</td>
</tr>
<tr>
<td>6</td>
<td>KCNH2</td>
<td>ES0D</td>
<td>1</td>
<td>2</td>
<td>50</td>
<td>–</td>
<td>[14]</td>
</tr>
<tr>
<td>7</td>
<td>KCNH2</td>
<td>T618I</td>
<td>4</td>
<td>4</td>
<td>100</td>
<td>–</td>
<td>[9]</td>
</tr>
<tr>
<td>8</td>
<td>KCNH2</td>
<td>T618I</td>
<td>2</td>
<td>2</td>
<td>100</td>
<td>–</td>
<td>[9]</td>
</tr>
<tr>
<td>9</td>
<td>KCNH2</td>
<td>T618I</td>
<td>3</td>
<td>3</td>
<td>100</td>
<td>–</td>
<td>Current study</td>
</tr>
<tr>
<td>10</td>
<td>KCNH2</td>
<td>Not reported</td>
<td>6</td>
<td>6</td>
<td>100</td>
<td>–</td>
<td>[12]</td>
</tr>
<tr>
<td>11</td>
<td>KCNQ1</td>
<td>V141M</td>
<td>1</td>
<td>2</td>
<td>50</td>
<td>AF, (b)</td>
<td>[9]</td>
</tr>
<tr>
<td>12</td>
<td>KCNQ1</td>
<td>D172N</td>
<td>2</td>
<td>2</td>
<td>100</td>
<td>–</td>
<td>[5]</td>
</tr>
<tr>
<td>13</td>
<td>KCNQ1</td>
<td>D172N</td>
<td>2</td>
<td>2</td>
<td>100</td>
<td>–</td>
<td>[6]</td>
</tr>
<tr>
<td>14</td>
<td>CACNA1C</td>
<td>G490R</td>
<td>2</td>
<td>3</td>
<td>67</td>
<td>–</td>
<td>Current study</td>
</tr>
<tr>
<td>15</td>
<td>CACNB2</td>
<td>S481L</td>
<td>4</td>
<td>6</td>
<td>67</td>
<td>–</td>
<td>Current study</td>
</tr>
<tr>
<td>16</td>
<td>CACNA2D1</td>
<td>S755T</td>
<td>1</td>
<td>3</td>
<td>33</td>
<td>–</td>
<td>[7]</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
<td>42</td>
<td>51</td>
<td>82%</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


(KCNQ1) patients tend to become symptomatic before the age of 10 years [45].

We found a higher prevalence of bradyarrhythmia and AF in KCNQ1 mutant carriers than for other genotypes (Fig. 5C,D, Table 3). A gain of function in IKs has not only been associated with SQTS but also with familial AF [46] and sinus bradycardia [47]. This is thought to be primarily because the APD shortening occurs in the atrium as well as in the ventricile, increasing the susceptibility of atrial tissue to sustained re-entry [48]. Furthermore, computer simulations of the SQTS mutation, KCNQ1-V141M, and the familial AF mutation, KCNQ1-V241K, demonstrated that a gain of function in Ik1 has been found to cause a cessation in spontaneous activity in the sinus node [15,47]. Such mechanisms may explain the observed phenotypic overlap and predominance of bradycardia and AF in SQT2.

5. Study limitations

In eight SQT2 patients we studied, six individuals carried the identical KCNQ1 mutation V141M. Therefore, the phenotype of the V141M mutation may be over-represented in our SQT2 data. As SQTS is a rare disease, the size of the population studied is small. Further delineation of this rare lethal arrhythmic syndrome warrants more extensive genetic and population studies using larger cohorts.

6. Conclusions

In summary, our study identified two KCNH2 mutations and one KCNQ1 mutation in five Japanese families with SQTS. The novel KCNH2-I560T mutation causes severe shortening of the QT interval and can trigger VF despite only a modest shift in inactivation. Among SQTS patients, there exist latent mutation carriers with ECG abnormalities such as AF and bradycardia indicating incomplete penetrance. Furthermore, despite the limited number of reported SQTS patients, our study suggests that clinical characteristics of SQTS can differ depending on the patient genotype, as is observed in LQTS.

Supplementary data to this article can be found online at http://dx.doi.org/10.1016/j.ijcard.2015.04.090.

Acknowledgments

We thank Dr. Tadashi Nakajima (Gunma University) for his assistance in sequencing our probands. We also thank Atsuko Iida, Saori Nakano, and Yasuko Noguchi for their technical assistance.

Funding source

This work was supported by Grant-in-Aid for Scientific Research on Innovative Areas (HD Physiology) 22136007, Grant-in-Aid for Scientific Research 24390199 from the Ministry of Education, Culture, Sports, Science and Technology, Japan, the Research Grant for the Cardiovascular Diseases (H24-033) from the Japanese Ministry of Health, Labour and Welfare (N.M.).

References


Conflict of Interest

None.